Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Treatment of hepatitis C virus genotype 4 in the DAA era.

Di Biagio A, Taramasso L, Cenderello G.

Virol J. 2018 Nov 22;15(1):180. doi: 10.1186/s12985-018-1094-4. Review.

2.

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.

Modica S, Rossetti B, Lombardi F, Lagi F, Maffeo M, D'Autilia R, Pecorari M, Vicenti I, Bruzzone B, Magnani G, Paolucci S, Francisci D, Penco G, Sacchini D, Zazzi M, De Luca A, Di Biagio A.

HIV Med. 2018 Nov 21. doi: 10.1111/hiv.12692. [Epub ahead of print]

PMID:
30461149
3.

Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.

Filaci G, Fenoglio D, Taramasso L, Indiveri F, Di Biagio A.

Front Immunol. 2018 Oct 23;9:2447. doi: 10.3389/fimmu.2018.02447. eCollection 2018.

4.

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.

Dentone C, Di Biagio A, Cozzi Lepri A, Fenoglio D, Filaci G, Lichtner M, Carrara S, Giacometti A, Sighinolfi L, Marchetti G, Antinori A, D'arminio Monforte A; ICONA Foundation Study Group.

HIV Clin Trials. 2018 Nov 13:1-5. doi: 10.1080/15284336.2018.1488453. [Epub ahead of print]

PMID:
30422095
5.

Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature.

Mirabella M, Taramasso L, Nicolini LA, Russo R, Viscoli C, Di Biagio A.

Clin Nephrol Case Stud. 2018 Oct 26;6:31-35. doi: 10.5414/CNCS109221. eCollection 2018.

6.

Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.

Riccardi N, Berruti M, Del Puente F, Taramasso L, Di Biagio A.

Recent Pat Antiinfect Drug Discov. 2018 Oct 31. doi: 10.2174/1574891X13666181031120019. [Epub ahead of print]

PMID:
30378502
7.

HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation.

Cenderello G, Taramasso L, Marra D, Orcamo P, Pasa A, Di Biagio A.

Expert Rev Pharmacoecon Outcomes Res. 2018 Oct 15:1-5. doi: 10.1080/14737167.2019.1537124. [Epub ahead of print]

PMID:
30321071
8.

How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy.

Taramasso L, Demma F, Bitonti R, Ferrazin A, Giannini B, Giacomini M, Beltramini S, Sasso E, Viscoli C, Di Biagio A.

BMC Health Serv Res. 2018 Sep 6;18(1):691. doi: 10.1186/s12913-018-3507-x.

9.

The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.

Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network.

Multidiscip Respir Med. 2018 Aug 9;13(Suppl 1):33. doi: 10.1186/s40248-018-0141-8. eCollection 2018.

10.

Modulation of the Natural Killer Cell Compartment during DAAs treatment in Interferon-naïve HCV patients: The type of DAA matters.

Nicolini LA, Dettori S, Bozzano F, Di Biagio A, De Maria A.

Immunol Lett. 2018 Nov;203:112-115. doi: 10.1016/j.imlet.2018.08.004. Epub 2018 Aug 23. No abstract available.

PMID:
30144471
11.

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).

Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, De Socio GV, Martinelli C, Gulminetti R, Maggi P, Orofino G, Vichi F, Di Biagio A, Bonfanti P; CISAI Study Group.

BMC Infect Dis. 2018 Jul 31;18(1):357. doi: 10.1186/s12879-018-3268-5.

12.

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study.

Gagliardini R, Ciccullo A, Borghetti A, Maggiolo F, Bartolozzi D, Borghi V, Pecorari M, Di Biagio A, Callegaro AP, Bruzzone B, Saladini F, Paolucci S, Maserati R, Zazzi M, Di Giambenedetto S, De Luca A; ARCA Study Group .

Open Forum Infect Dis. 2018 May 15;5(6):ofy113. doi: 10.1093/ofid/ofy113. eCollection 2018 Jun.

13.

Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).

Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, Francisci D, Monno L, Punzi G, Meraviglia P, Paolucci S, Di Biagio A, Bruzzone B, Mancon A, Micheli V, Zazzi M; ARCA (Antiviral Response Cohort Analysis).

J Clin Virol. 2018 Aug;105:112-117. doi: 10.1016/j.jcv.2018.06.012. Epub 2018 Jun 21.

PMID:
29957545
14.

A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical Practice.

Di Biagio A, Riccardi N, Rusconi S, Guaraldi G, Borderi M, De Luca A, Gianotti N, Lo Caputo S, Maggi P, Maserati R, Maggiolo F.

AIDS Rev. 2018 Apr-Jun;20(2):75-82. Review.

PMID:
29938701
15.

Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course.

Nicolini LA, Magne F, Signori A, Di Biagio A, Sticchi L, Paganino C, Durando P, Viscoli C.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):922-928. doi: 10.1089/AID.2017.0070. Epub 2018 Aug 16.

PMID:
29926738
16.

First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.

Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group.

HIV Med. 2018 May 30. doi: 10.1111/hiv.12628. [Epub ahead of print]

PMID:
29846042
17.

Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.

Borderi M, Angarano G, Antinori A, Chirianni A, Cinque P, D'Arminio Monforte A, Di Biagio A, Di Perri G, Galli M, Gori A, Lazzarin A, Mussini C, Perno CF, Quirino T, Rizzardini G, Calza L, Viale P, Acone B, Andreoni M.

New Microbiol. 2018 Apr;41(2):112-117.

18.

Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment.

Taramasso L, Montanari L, Di Biagio A.

AIDS. 2018 Jun 1;32(9):1202-1203. doi: 10.1097/QAD.0000000000001804. No abstract available.

PMID:
29746321
19.

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.

Bagella P, De Socio GV, Ricci E, Menzaghi B, Martinelli C, Squillace N, Maggi P, Orofino G, Calza L, Carenzi L, Celesia BM, Penco G, Di Biagio A, Valsecchi L, Vichi F, Colombo V, Parruti G, Dentone C, Falasca K, Bonfanti P, Madeddu G; C.I.S.A.I. Study Group, Italy.

Infect Drug Resist. 2018 Apr 26;11:615-623. doi: 10.2147/IDR.S152090. eCollection 2018.

20.

Electronic Health Records: From the Management of Patients to the Research Use of Clinical Data.

Giannini B, Curtaz F, Del Puente F, Di Biagio A, Giacomini M.

Stud Health Technol Inform. 2018;247:246-250.

PMID:
29677960
21.

Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients.

Taramasso L, Mirabella M, Cappadona F, Bonino B, Riccardi N, Cenderello G, De Socio GV, Viscoli C, Viazzi F, Di Biagio A.

Curr Hypertens Rev. 2018;14(1):48-55. doi: 10.2174/1573402114666180307145051.

PMID:
29521243
22.

Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy.

Prinapori R, Giannini B, Riccardi N, Bovis F, Giacomini M, Setti M, Viscoli C, Artioli S, Di Biagio A.

Epidemiol Infect. 2018 Apr;146(5):606-611. doi: 10.1017/S0950268817003107. Epub 2018 Feb 28.

PMID:
29486818
23.

Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.

Capetti AF, Cossu MV, Sterrantino G, Barbarini G, Di Giambenedetto S, De Socio GV, Orofino G, Di Biagio A, Celesia BM, Rusconi S, Argenteri B, Rizzardini G.

Ann Pharmacother. 2018 Aug;52(8):740-746. doi: 10.1177/1060028018761600. Epub 2018 Feb 26.

PMID:
29482352
24.

From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital Platform Improved Doctors' Work and Patients' Care.

Giannini B, Riccardi N, Cenderello G, Di Biagio A, Dentone C, Giacomini M.

AIDS Res Hum Retroviruses. 2018 Mar;34(3):239-240. doi: 10.1089/aid.2017.0064. Epub 2018 Feb 21. No abstract available.

PMID:
29466022
25.

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.

Taramasso L, Di Biagio A, Bovis F, Nicolini LA, Antinori A, Milazzo L, Sollima S, Gubertini G, Niero F, Saracino A, Bruno R, Borghi V, Montagnani F, Cattelan A, Hasson H, Taliani G, D'Arminio Monforte A, Mastroianni C, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Cacopardo B, Giacometti A, Parruti G, Vullo V, Chirianni A, Teti E, Pasquazzi C, Segala D, Andreoni M.

PLoS One. 2018 Feb 20;13(2):e0192627. doi: 10.1371/journal.pone.0192627. eCollection 2018.

26.

Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing.

Riccardi N, Giannini B, Borghesi ML, Taramasso L, Cattaneo E, Cenderello G, Toscanini F, Giacomini M, Pontali E, Cassola G, Viscoli C, Di Biagio A.

ERJ Open Res. 2018 Feb 2;4(1). pii: 00108-2017. doi: 10.1183/23120541.00108-2017. eCollection 2018 Jan.

27.

Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience.

Vitiello P, Taramasso L, Ricci E, Maggi P, Martinelli C, Gabrielli C, Vittorio De Socio G, Di Cristo V, Rusconi S, Falasca K, Menzaghi B, Tebini A, Di Biagio A; CISAI Study Group.

J Women Aging. 2018 Jan 25:1-13. doi: 10.1080/08952841.2018.1428100. [Epub ahead of print]

PMID:
29369016
28.

HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients.

Saracino A, Cozzi-Lepri A, Shanyinde M, Ceccherini Silberstein F, Nozza S, Di Biagio A, Cassola G, Bruno G, Capobianchi M, Puoti M, Monno L, d'Arminio Monforte A; ICONA Foundation Study.

PLoS One. 2018 Jan 11;13(1):e0190302. doi: 10.1371/journal.pone.0190302. eCollection 2018.

29.

Weight Gain: A Possible Side Effect of All Antiretrovirals.

Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, Martinelli CV, De Socio GV, Squillace N, Rusconi S, Bonfanti P, Di Biagio A; CISAI Study Group .

Open Forum Infect Dis. 2017 Nov 3;4(4):ofx239. doi: 10.1093/ofid/ofx239. eCollection 2017 Fall.

30.

Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy.

Pittalis S, Piselli P, Contini S, Gualano G, Alma MG, Tadolini M, Piccioni P, Bocchino M, Matteelli A, Bonora S, Di Biagio A, Franzetti F, Carbonara S, Gori A, Sotgiu G, Palmieri F, Ippolito G, Girardi E.

PLoS One. 2017 Dec 18;12(12):e0189425. doi: 10.1371/journal.pone.0189425. eCollection 2017.

31.

Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation.

Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD.

AIDS Patient Care STDS. 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140.

PMID:
29211512
32.

Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?

Taramasso L, Riccardi N, Del Puente F, Bruzzone B, Ripamonti D, D'Ambrosio B, Viscoli C, Di Biagio A.

AIDS Res Hum Retroviruses. 2018 Feb;34(2):168-170. doi: 10.1089/AID.2017.0112. Epub 2018 Jan 18.

PMID:
29166777
33.

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.

Rossetti B, Gagliardini R, Meini G, Sterrantino G, Colangeli V, Re MC, Latini A, Colafigli M, Vignale F, Rusconi S, Micheli V, Di Biagio A, Orofino G, Ghisetti V, Fantauzzi A, Vullo V, Grima P, Francisci D, Mastroianni C, Antinori A, Trezzi M, Lisi L, Navarra P, Canovari B, D'Arminio Monforte A, Lamonica S, D'Avino A, Zazzi M, Di Giambenedetto S, De Luca A; for GUSTA trial study group.

PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

34.

CD8+CD28-CD127loCD39+ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?

Fenoglio D, Dentone C, Signori A, Di Biagio A, Parodi A, Kalli F, Nasi G, Curto M, Cenderello G, De Leo P, Bartolacci V, Orofino G, Nicolini LA, Taramasso L, Fiorillo E, Orrù V, Traverso P, Bruzzone B, Ivaldi F, Mantia E, Guerra M, Negrini S, Giacomini M, Bhagani S, Filaci G.

J Allergy Clin Immunol. 2018 Jun;141(6):2220-2233.e4. doi: 10.1016/j.jaci.2017.08.021. Epub 2017 Nov 2.

35.

Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents.

Taramasso L, Cenderello G, Riccardi N, Tunesi S, Di Biagio A.

New Microbiol. 2017 Oct;40(4):227-233. Epub 2017 Oct 10. Review.

36.

Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.

Marras F, Casabianca A, Bozzano F, Ascierto ML, Orlandi C, Di Biagio A, Pontali E, Dentone C, Orofino G, Nicolini L, Taramasso L, Magnani M, Marincola FM, Wang E, Moretta L, De Maria A.

J Virol. 2017 Nov 14;91(23). pii: e00647-17. doi: 10.1128/JVI.00647-17. Print 2017 Dec 1.

37.

Cardiovascular risk and dyslipidemia among persons living with HIV: a review.

Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N.

BMC Infect Dis. 2017 Aug 9;17(1):551. doi: 10.1186/s12879-017-2626-z. Review.

38.

PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection.

Di Biagio A, Riccardi N, Signori A, Maserati R, Nozza S, Gori A, Bonora S, Borderi M, Ripamonti D, Rossi MC, Orofino G, Quirino T, Nunnari G, Celesia BM, Martini S, Sagnelli C, Mazzola G, Colletti P, Bartolozzi D, Bini T, Ladisa N, Castelnuovo F, Saracino A, Lo Caputo S.

PLoS One. 2017 Jul 20;12(7):e0181433. doi: 10.1371/journal.pone.0181433. eCollection 2017.

39.

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.

Squillace N, Ricci E, Quirino T, Gori A, Bandera A, Carenzi L, De Socio GV, Orofino G, Martinelli C, Madeddu G, Rusconi S, Maggi P, Celesia BM, Cordier L, Vichi F, Calza L, Falasca K, Di Biagio A, Pellicanò GF, Bonfanti P; CISAI Study Group.

PLoS One. 2017 Jun 20;12(6):e0179254. doi: 10.1371/journal.pone.0179254. eCollection 2017.

40.

Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.

Riccardi N, Del Puente F, Magnè F, Taramasso L, Di Biagio A.

Recent Pat Antiinfect Drug Discov. 2018;13(1):3-11. doi: 10.2174/1574891X12666170619101904. Review.

PMID:
28625141
41.

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.

Cenderello G, Fanizza C, Marenco S, Nicolini LA, Artioli S, Baldissarro I, Dentone C, De Leo P, Di Biagio A.

Clinicoecon Outcomes Res. 2017 May 22;9:281-293. doi: 10.2147/CEOR.S129859. eCollection 2017.

42.

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Cento V, Nguyen THT, Di Carlo D, Biliotti E, Gianserra L, Lenci I, Di Paolo D, Calvaruso V, Teti E, Cerrone M, Romagnoli D, Melis M, Danieli E, Menzaghi B, Polilli E, Siciliano M, Nicolini LA, Di Biagio A, Magni CF, Bolis M, Antonucci FP, Di Maio VC, Alfieri R, Sarmati L, Casalino P, Bernardini S, Micheli V, Rizzardini G, Parruti G, Quirino T, Puoti M, Babudieri S, D'Arminio Monforte A, Andreoni M, Craxì A, Angelico M, Pasquazzi C, Taliani G, Guedj J, Perno CF, Ceccherini-Silberstein F.

PLoS One. 2017 May 18;12(5):e0177352. doi: 10.1371/journal.pone.0177352. eCollection 2017.

43.

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2016.

Antinori A, Di Biagio A, Marcotullio S, Andreoni M, Chirianni A, d'Arminio Monforte A, Galli M, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group.

New Microbiol. 2017 Apr;40(2):86-98.

44.

A Web Based Tool to Enhance Monitoring and Retention in Care for Tuberculosis Affected Patients.

Giannini B, Riccardi N, Di Biagio A, Cenderello G, Giacomini M.

Stud Health Technol Inform. 2017;237:204-208.

PMID:
28479569
45.

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A, De Luca A, Gianotti N, Di Biagio A, Antinori A; Icona Foundation Study Group.

Infection. 2017 Aug;45(4):521-528. doi: 10.1007/s15010-017-1018-z. Epub 2017 May 5.

PMID:
28477212
46.

Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?

Taramasso L, Ricci E, Celesia BM, Bonfanti P, Quirino T, Squillace N, Nicolini LA, Maggi P, Martinelli C, De Socio GV, Di Biagio A; on behalf CISAI Study Group.

Clin Res Hepatol Gastroenterol. 2017 Oct;41(5):e76-e79. doi: 10.1016/j.clinre.2017.03.006. Epub 2017 Apr 21. No abstract available.

PMID:
28438572
47.

Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital: a 30-year retrospective study.

Grignolo S, Agnello R, Gerbaldo D, Gotta C, Alicino C, Del Puente F, Taramasso L, Bruzzone B, Gustavino C, Trasino S, DE Maria A, Icardi G, Viscoli C, DI Biagio A.

Epidemiol Infect. 2017 Jun;145(8):1658-1669. doi: 10.1017/S095026881700053X. Epub 2017 Mar 22.

PMID:
28325171
48.

Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era: Neglected no more?

Riccardi N, Nosenzo F, Peraldo F, Sarocchi F, Taramasso L, Traverso P, Viscoli C, Di Biagio A, Derchi LE, De Maria A.

PLoS Negl Trop Dis. 2017 Mar 16;11(3):e0005237. doi: 10.1371/journal.pntd.0005237. eCollection 2017 Mar. No abstract available.

49.

Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?

Di Biagio A, Ameri M, Sirello D, Cenderello G, Di Bella E, Taramasso L, Giannini B, Giacomini M, Viscoli C, Cassola G, Montefiori M.

BMC Infect Dis. 2017 Feb 6;17(1):127. doi: 10.1186/s12879-017-2199-x.

50.

Quality of life in an Italian cohort of people living with HIV in the era of combined antiretroviral therapy (Evidence from I.A.N.U.A. study-investigation on antiretroviral therapy).

Venturini A, Cenderello G, Di Biagio A, Giannini B, Ameri M, Giacomini M, Montefiori M, Setti M, Mazzarello G, Merlano C, Orcamo P, Viscoli C, Cassola G.

AIDS Care. 2017 Nov;29(11):1373-1377. doi: 10.1080/09540121.2017.1286286. Epub 2017 Feb 2.

PMID:
28150510

Supplemental Content

Loading ...
Support Center